Journal of Gastrointestinal Surgery

, Volume 14, Issue 5, pp 891–898 | Cite as

Surgery and Staging of Pancreatic Neuroendocrine Tumors: A 14-Year Experience

  • Hiromichi Ito
  • Michael Abramson
  • Kaori Ito
  • Edward Swanson
  • Nancy Cho
  • Daniel T. Ruan
  • Richard S. Swanson
  • Edward E. WhangEmail author
Original Article



The aims of this study were to evaluate contemporary outcomes associated with the surgical management of pancreatic neuroendocrine tumors (PNETs) and to assess the prognostic value of the World Health Organization (WHO) classification and TNM staging for PNETs.


The medical records of 73 consecutive patients with PNETs treated at a single institution from January 1992 through September 2006 were reviewed. Survival was analyzed with the Kaplan-Meier method (median follow-up: 43 months).


Median patient age was 52 years (range, 19-83 years), and 36 (49%) patients were male. Thirty-three patients had a well-differentiated neuroendocrine tumor (WDT), 26 had a well-differentiated neuroendocrine carcinoma (WDCa), and 14 had a poorly differentiated neuroendocrine carcinoma (PDCa). Fifty (68%) patients underwent potentially curative resection, and the 5-year disease-specific survival (DSS) rate for the entire cohort was 62%. WHO classification and TNM staging system provided good prognostic stratification of patients; 5-year DSS rates were 100% for WDT, 57% for WDCa, 8% for PDCa, respectively, by WHO classification (p < 0.001), and 100% for stage 1, 90% for stage 2, 57% for stage 3, and 8% for stage 4, respectively, by TNM stage (p < 0.001). Among the patients who underwent potentially curative resection, nodal status, distant metastasis, and tumor grade were significant prognostic factors.


WHO classification and TNM staging are useful for prognostic stratification among patients with PNETs.


Pancreatic neuroendocrine tumor Surgery Staging 


  1. 1.
    Fesinmeyer MD, Austin MA, Li CI, et al. Differences in survival by histologic type of pancreatic cancer. Cancer Epidemiol Biomarkers Prev 2005;14(7):1766–1773.CrossRefPubMedGoogle Scholar
  2. 2.
    Gumbs AA, Moore PS, Falconi M, et al. Review of the clinical, histological, and molecular aspects of pancreatic endocrine neoplasms. J Surg Oncol 2002;81(1):45–53; discussion 54CrossRefPubMedGoogle Scholar
  3. 3.
    House MG, Schulick RD. Endocrine tumors of the pancreas. Curr Opin Oncol 2006;18(1):23–29.CrossRefPubMedGoogle Scholar
  4. 4.
    Bilimoria KY, Talamonti MS, Tomlinson JS, et al. Prognostic score predicting survival after resection of pancreatic neuroendocrine tumors: analysis of 3851 patients. Ann Surg 2008;247(3):490–500.CrossRefPubMedGoogle Scholar
  5. 5.
    Kloppel G, Perren A, Heitz PU. The gastroenteropancreatic neuroendocrine cell system and its tumors: the WHO classification. Ann N Y Acad Sci 2004;1014:13–27.CrossRefPubMedGoogle Scholar
  6. 6.
    Rindi G, Kloppel G, Alhman H, et al. TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch 2006;449(4):395–401.CrossRefPubMedGoogle Scholar
  7. 7.
    Ferrone CR, Tang LH, Tomlinson J, et al. Determining prognosis in patients with pancreatic endocrine neoplasms: can the WHO classification system be simplified? J Clin Oncol 2007;25(35):5609–5615.CrossRefPubMedGoogle Scholar
  8. 8.
    Kaplan F, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;63:475–481.Google Scholar
  9. 9.
    Fitzgerald TL, Hickner ZJ, Schmitz M, Kort EJ. Changing incidence of pancreatic neoplasms: a 16-year review of statewide tumor registry. Pancreas 2008;37(2):134–138.CrossRefPubMedGoogle Scholar
  10. 10.
    Kazanjian KK, Reber HA, Hines OJ. Resection of pancreatic neuroendocrine tumors: results of 70 cases. Arch Surg 2006;141(8):765–769; discussion 769–770CrossRefPubMedGoogle Scholar
  11. 11.
    Nguyen SQ, Angel LP, Divino CM, et al. Surgery in malignant pancreatic neuroendocrine tumors. J Surg Oncol 2007;96(5):397–403.CrossRefPubMedGoogle Scholar
  12. 12.
    Phan GQ, Yeo CJ, Cameron JL, et al. Pancreaticoduodenectomy for selected periampullary neuroendocrine tumors: fifty patients. Surgery 1997;122(6):989–996; discussion, 996–997CrossRefPubMedGoogle Scholar
  13. 13.
    Bilimoria KY, Bentrem DJ, Merkow RP, et al. Application of the pancreatic adenocarcinoma staging system to pancreatic neuroendocrine tumors. J Am Coll Surg 2007;205(4):558–563.CrossRefPubMedGoogle Scholar
  14. 14.
    Tomassetti P, Campana D, Piscitelli L, et al. Endocrine pancreatic tumors: factors correlated with survival. Ann Oncol 2005;16(11):1806–1810.CrossRefPubMedGoogle Scholar
  15. 15.
    Norton JA, Fraker DL, Alexander HR, et al. Surgery to cure the Zollinger-Ellison syndrome. N Engl J Med 1999;341(9):635–644.CrossRefPubMedGoogle Scholar
  16. 16.
    Nikfarjam M, Warshaw AL, Axelrod L, et al. Improved contemporary surgical management of insulinomas: a 25-year experience at the Massachusetts General Hospital. Ann Surg 2008;247(1):165–172.CrossRefPubMedGoogle Scholar
  17. 17.
    Pitt SC, Pitt HA, Baker MS, et al. Small pancreatic and periampullary neuroendocrine tumors: resect or enucleate? J Gastrointest Surg 2009;13(9):1692–1698.CrossRefPubMedGoogle Scholar
  18. 18.
    Schurr PG, Strate T, Rese K, et al. Aggressive surgery improves long-term survival in neuroendocrine pancreatic tumors: an institutional experience. Ann Surg 2007;245(2):273–281.CrossRefPubMedGoogle Scholar
  19. 19.
    Lo CY, van Heerden JA, Thompson GB, et al. Islet cell carcinoma of the pancreas. World J Surg 1996;20(7):878–883; discussion 884CrossRefPubMedGoogle Scholar
  20. 20.
    Solorzano CC, Lee JE, Pisters PW, et al. Nonfunctioning islet cell carcinoma of the pancreas: survival results in a contemporary series of 163 patients. Surgery 2001;130(6):1078–1085.CrossRefPubMedGoogle Scholar
  21. 21.
    Chu QD, Hill HC, Douglass HO, Jr., et al. Predictive factors associated with long-term survival in patients with neuroendocrine tumors of the pancreas. Ann Surg Oncol 2002;9(9):855–862.CrossRefPubMedGoogle Scholar
  22. 22.
    Hochwald SN, Zee S, Conlon KC, et al. Prognostic factors in pancreatic endocrine neoplasms: an analysis of 136 cases with a proposal for low-grade and intermediate-grade groups. J Clin Oncol 2002;20(11):2633–2642.CrossRefPubMedGoogle Scholar
  23. 23.
    Bloomston M, Muscarella P, Shah MH, et al. Cytoreduction results in high perioperative mortality and decreased survival in patients undergoing pancreatectomy for neuroendocrine tumors of the pancreas. J Gastrointest Surg 2006;10(10):1361–1370.CrossRefPubMedGoogle Scholar
  24. 24.
    Teh SH, Deveney C, Sheppard BC. Aggressive pancreatic resection for primary pancreatic neuroendocrine tumor: is it justifiable? Am J Surg 2007;193(5):610–613; discussion 613CrossRefPubMedGoogle Scholar
  25. 25.
    Vagefi PA, Razo O, Deshpande V, et al. Evolving patterns in the detection and outcomes of pancreatic neuroendocrine neoplasms: the Massachusetts General Hospital experience from 1977 to 2005. Arch Surg 2007;142(4):347–354.CrossRefPubMedGoogle Scholar
  26. 26.
    Fischer L, Kleeff J, Esposito I, et al. Clinical outcome and long-term survival in 118 consecutive patients with neuroendocrine tumours of the pancreas. Br J Surg 2008;95(5):627–635.CrossRefPubMedGoogle Scholar

Copyright information

© The Society for Surgery of the Alimentary Tract 2010

Authors and Affiliations

  • Hiromichi Ito
    • 1
  • Michael Abramson
    • 1
  • Kaori Ito
    • 1
  • Edward Swanson
    • 1
  • Nancy Cho
    • 1
  • Daniel T. Ruan
    • 1
  • Richard S. Swanson
    • 1
  • Edward E. Whang
    • 1
    Email author
  1. 1.Department of SurgeryBrigham and Women’s Hospital, Harvard Medical SchoolBostonUSA

Personalised recommendations